Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Overtly healthy male or a female (not pregnant and agreeable to take birth control measures until study completion)~* Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²)~* Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study~* Are nonsmokers, have not smoked for at least 6 months prior to entering the study~Exclusion Criteria:~* Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study~* Have previously participated or withdrawn from this study~* Had blood loss of more than 450 milliliters (mL) within the last 3 months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- LY900014 (SC Abdomen) (Type: EXPERIMENTAL): Single dose of 15-U of LY900014 administered subcutaneously (SC) into the abdomen in one period
- LY900014 (SC Thigh) (Type: EXPERIMENTAL): Single dose of 15-U of LY900014 administered SC into the thigh in one period
- LY900014 (SC Arm) (Type: EXPERIMENTAL): Single dose of 15-U of LY900014 administered SC into the arm (deltoid) in one period
- LY900014 (IV) (Type: ACTIVE_COMPARATOR): Single dose of 15-U of LY900014 administered intravenously (IV) in one period

Based on this trial design, predict the completion outcome and termination type (if applicable).